Core Insights - Maravai LifeSciences Holdings, Inc. has appointed Rajesh "Raj" Asarpota as Executive Vice President and Chief Financial Officer, effective June 30, 2025, succeeding Kevin Herde who will transition to an advisory role [1][2][6] Leadership Transition - Kevin Herde has been recognized for his eight years of leadership, contributing significantly to the company's foundation, and will continue to support the transition in an advisory capacity [2][5] - Raj Asarpota brings nearly 30 years of executive leadership experience, including over 10 years as CFO in life sciences and medical device companies, with a strong track record in driving performance and strategic initiatives [2][8] Strategic Role - As CFO, Asarpota will oversee Maravai's global Finance, Accounting, Treasury, Investor Relations, Corporate Strategy, and Information Technology teams, playing a critical role in executing the company's growth and profitability strategy [3][4] - The leadership transition aims to strengthen the executive team focused on innovation, execution, and financial performance, enhancing the company's ability to deliver differentiated solutions globally [5] Company Vision - Asarpota expressed enthusiasm about joining Maravai, highlighting the company's meaningful mission and potential for impact, and aims to create lasting value for customers and shareholders [6][8] - Maravai LifeSciences is recognized for providing critical products that support drug therapies, diagnostics, and novel vaccines, positioning itself as a leader in nucleic acid synthesis and biologics safety testing [10]